AI-Driven Prostate Cancer Test Promises 96% Accuracy

The new test, developed by UK scientists, combines over 100 biomarkers with AI analysis to improve early detection and risk assessment for prostate cancer.

• The test, created by EDX Medical Group, uses AI to analyze blood and urine samples for more than 100 prostate-related biomarkers.
• It aims to diagnose prostate cancer with 96% accuracy, assess its stage, aggression, and sub-type, and predict risk based on genetic factors.
• Prostate cancer is the most commonly diagnosed cancer in England, with over 55,000 cases annually, but no national screening program currently exists due to unreliable tests like PSA.
• Clinical trials are underway to validate the test’s effectiveness, and the company plans to seek regulatory approval in the UK and US this year.
• Olympic cyclist Sir Chris Hoy, who has terminal prostate cancer, has advocated for better screening and supports this initiative as a potential breakthrough.

3 Articles

The Independent The Telegraph The Times